Research progress in the regulatory mechanism of tumor-associated intronic enhancer region SNPs

doi:10.16352/j.issn.1001-6325.2026.07.1009

Abstract

Abstract: single nucleotide polymorphisms(SNPs) are the most common genetic polymorphisms. Intronic enhancer region SNPs(IER-SNPs) can influence the progress of carcinomaigenesis and progression of breast cancer, colorectal cancer, lung cancer and other carcinomas by multiple approaches including influencing the transcription factor binding,promoter-enhancer interactions and mediating the enhancer-promoter switching effect and so on. By sorting out the regulatory mechanisms of IER-SNPs on tumors, it can provide references for screening tumor-associated IER-SNPs formation and development and or research on regulatory mechanisms of these IER-SNPs.

Key words: carcinoma, intron, single nucleotide polymorphism(SNP), enhancer, regulation

CLC Number:

R394.3
R73

LI Xianqun, CHI Yuxin, MIAO Jiaming, QI Xiaolu, WEI Tong, YANG Weihong. Research progress in the regulatory mechanism of tumor-associated intronic enhancer region SNPs[J]. Basic & Clinical Medicine, 2026, 46(7): 1009-1013.

References

[1] Shi Q, Yao XY, Wang HY, et al. Breast cancer-associated SNP rs72755295 is a cis-regulatory variation for human EXO1[J]. Genet Mol Biol, 2022, 45: e20210420. doi: 10.1590/1678-4685-GMB-2021-0420.
[2] Shi Q, Zhang XX, Shi XQ, et al. Identification of rs2736099 as a novel cis-regulatory variation for TERT and implications for tumorigenesis and cell proliferation[J]. J Cancer Res Clin, 2023, 149: 4515-4522. doi:10.1007/s00432-022-04372-9
[3] Han D, Owiredu JN, Healy BM, et al. Susceptibility-associated geenetic variation in NEDD9 contributes to prostate cancer initiation and progression[J].Cancer Res, 2021, 81: 3766-3776. doi:10.1158/0008-5472.CAN-20-3042.
[4] Yu CY, Han JX, Zhang J, et al. A 16q22.1 variant confers susceptibility to colorectal cancer as a distal regulator of ZFP90[J]. Oncogene, 2020, 39: 1347-1360. doi:10.1038/s41388-019-1055-4.
[5] Ünal P, Lu Y, Bueno-de-Mesquita B, et al. Polymorphisms in transcription factor binding sites and enhancer regions and pancreatic ductal adenocarcinoma risk[J]. Hum Genomics, 2024, 18: 12. doi: 10.1186/s40246-024-00576-x.
[6] Protze J, Naas S, Krueger R, et al. The renal cancer risk allele at 14q24.2 activates a novel hypoxia-inducible transcription factor-binding enhancer of DPF3 expression[J]. J Biol Chem, 2022, 298: 101699. doi: 10.1016/j.jbc.2022.101699.
[7] Zhang ZH, Liu XP, Li L, et al. SNP rs4971059 predisposes to breast carcinogenesis and chemoresistance via TRIM46-mediated HDAC1 degradation[J]. Embo J, 2021, 40: e107974. doi: 10.15252/embj.2021107974.
[8] Lu Z, Fan L, Zhang F, et al. HSPA12A was identified as a key driver in colorectal cancer GWAS loci 10q26.12 and modulated by an enhancer-promoter interaction[J]. Arch Toxicol, 2023, 97: 2015-2028. doi: 10.1007/s00204-023-03494-4.
[9] Mei S, Ke J, Tian J, et al. A functional variant in the boundary of a topological association domain is associated with pancreatic cancer risk[J]. Mol Carcinogen, 2019, 58: 1855-1862. doi: 10.1002/mc.23077.
[10] Hua JT, Ahmed M, Guo H, et al. Risk SNP-mediated promoter-enhancer switching drives prostate cancer through lncRNA PCAT19[J]. Cell, 2018, 174: 564-575. doi: 10.1016/j.cell.2018.06.014.
[11] Baili E, Gazoul M, Lazaris AC, et al. Associations of long non-coding RNAs HOTAIR, LINC00951, POLR2E and HULC polymorphisms with the risk of esophageal and esophagogastric junction cancer in a western population: a case-control study[J]. Mol Biol Rep. 2024, 51:249. doi: 10.1007/s11033-024-09206-0.
[12] Karajovic J, Kovacevic B, Uzelac B, et al. Association of HOTAIR, MIR155HG, TERC, miR-155,-196a2, and-146a genes polymorphisms with papillary thyroid cancer susceptibility and prognosis[J]. Cancers, 2024, 16:485. doi: 10.3390/cancers16030485.
[13] Sherif ZA, Oguwob OO, Ressom HW. Mechanisms and technologies in cancer epigenetics[J]. Front Oncol. 2025, 14:1513654. doi: 10.3389/fonc.2024.1513654.
[14] Sudunagunta VS, Viny AD. Untangling the loops of STAG2 mutations in myelodysplastic syndrome[J]. Leuk Lymphoma. 2025, 66:6-15. doi: 10.1080/10428194.2024.2400210.
[15] Sole-Ferran M, Losada A. Cohesin in 3D: development, differentiation, and disease[J]. Genes Dev. 2025, 39:679-696. doi: 10.1101/gad.352671.125.
[16] Sun J, Chen Y, Xu Z, et al. Notch signaling in the tumor immune microenvironment of colorectal cancer: mechanisms and therapeutic opportunities[J]. J Transl Med. 2025, 23:315. doi: 10.1186/s12967-025-06282-z.
[17] Sayers EW, Beck J, Bolton EE, et al. Database resources of the National Center for Biotechnology Information[J]. Nucleic Acids Res. 2024, 52:D33-D43. doi: 10.1093/nar/gkab1112.
[18] Dong S, Zhao N, Spragins E, et al. Annotating and prioritizing human non-coding variants with RegulomeDB v.2[J]. Nat Genet, 2023, 55: 724-726. doi: 10.1038/s41588-023-01365-3.
[19] Zhu QN, Wang RX. Study on the association between CYP2D6*10 polymorphism and adverse reactions to Tamoxifen[J]. Chin J oncol, 2025, 47:404-410. doi: 10.3760/cma.j.cn112152-20240613-00251.
[20] Cerezo M, Sollis E, Ji Y, et al. The NHGRI-EBI GWAS catalog: standards for reusability, sustainability and diversity[J]. Nucleic Acids Res[J]. 2025, 53:D998-D1005. doi: 10.1093/nar/gkae1070.
[21] Raney BJ, Barber GP, Benet-Pages A, et al. The UCSC Genome Browser database: 2024 update[J]. Nucleic Acids Res, 2024, 52: 1082-1088. doi: 10.1093/nar/gkad987.
[22] Prabhu NB, Vinay CM, Satyamoorth K, et al. Pharmacogenomics deliberations of 2-deoxy-d-glucose in the treatment of COVID-19 disease: an in silico approach[J]. 3 Biotech. 2022, 12:287. doi: 10.1007/s13205-022-03363-4.
[23] Rauluseviciute I, Riudavets-Puig R, Blanc-Mathieu R, et al. JASPAR 2024: 20th anniversary of the open-access database of transcription factor binding profiles[J]. Nucleic Acids Res, 2023, 52: 174-182. doi: 10.1093/nar/gkad1059.
[24] He J, Huo X, Pei G, et al. Dual-role transcription factors stabilize intermediate expression levels[J]. Cell, 2024, 187: 2746-2766. doi: 10.1016/j.cell.2024.03.023.
[25] Zhang Z, Fang T, Chen L, et al. Multi-omics Mendelian randomization integrating GWAS, eQTL, and mQTL data identified genes associated with breast cancer[J]. Am J Cancer Res. 2024, 14:1433-1445. doi: 10.62347/BCZW1355.